US and Zambia Clash Over Stalled $1 Billion Health Deal Amid HIV Crisis

The United States has criticized the Zambian government for a lack of engagement regarding a stalled health aid agreement worth more than $1 billion, as tensions rise over the conditions attached to the funding. The five-year package, which was originally intended for signing in November 2025, is designed to combat malaria and HIV, improve maternal and child health, and strengthen preparedness for disease outbreaks.

The diplomatic friction centers on accusations that the U.S. Is leveraging life-saving health assistance to secure greater access to Zambia’s critical mineral resources, specifically copper. Zambia is the second largest copper producer in Africa, and the U.S. Has sought expanded access to these minerals as part of broader strategic goals.

Dispute Over National Interests

Zambian officials have pushed back on the deal, stating that certain provisions do not align with the country’s national interests. According to reports from Reuters and Africa Business Insight, the Zambian government has postponed the agreement due to concerns over sensitive data sharing and the potential linking of health aid to mining access.

Under the proposed terms, Zambia would have been required to contribute approximately $34 million toward the initiative. The U.S. Has dismissed claims that the health deal is being used as a tool for mineral leverage, describing such accusations as patently false.

Impact on HIV and Health Services

The stalemate comes amid a precarious health landscape in Zambia, where more than a million people live with HIV. For over two decades, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has served as a cornerstone for financing medical treatment in the region.

Reporting from the New York Times and NPR indicates that HIV and AIDS have begun to creep back into parts of Zambia following previous cuts to U.S. Assistance. Patients have reported struggling to find essential medication, leading to increased risks of illness and death for those dependent on U.S.-funded programs.

While the Trump administration has maintained that HIV medications have survived foreign aid cuts, local reports from Zambia suggest a different reality on the ground. Healthcare workers and patients have described a shortage of pills, leaving many to grapple with the fallout of sudden funding reductions.

Strategic Stakes

The dispute highlights a growing intersection between global health diplomacy and the race for critical minerals. A policy memo seen by the New York Times suggested that the U.S. Had considered cutting HIV and health support to Zambia as a means to secure mineral access, further fueling suspicions within the Zambian government.

As of May 1, 2026, the U.S. Continues to urge Zambia to engage in the finalization of the $1 billion deal to prevent further disruptions to health services. The Zambian government remains hesitant to sign the agreement until the provisions are reconciled with its national interests.